Arch Therapeutics (OTCMKTS: ARTH) and Mazor Robotics (NASDAQ: MZOR) are both small medical companies, but which is the top stock? We will compare the two companies based on the dividend's power, valuation, analyst's recommendations, risk, institutional ownership, earnings and profitability.
Earnings and valuation
This table compares top-line earnings of Arch Therapeutics and Mazor Robotics, earnings per share and valuation.
|Gross income||Price / sales ratio||Net income||Earnings per share||Price / earnings ratio|
|Arch Therapeutics||N / A||N / A||– $ 7.78 million||($ 0.05)||-7.80|
|Mazor Robotics||$ 64.95 million||23.64||– $ 12.41 million||($ 0.50)||-116.64|
Arch Therapeutics has higher earnings, but lower incomes than Mazor Robotics. Mazor Robotics is trading at a lower price / revenue ratio than Arch Therapeutics, indicating that it is currently more accessible than the two stocks.
Volatility and risk
Arch Therapeutics has a beta of 0.83, indicating that the share price is 17% less volatile than the S & P 500. By comparison, Mazor Robotics has a beta of 1.32, indicating that the share price is 32% volatile than the S & P 500.
This is a breakdown of current ratings and recommendations for Arch Therapeutics and Mazor Robotics, reported by MarketBeat.com.
|We sell ratings||Keep your ratings||Buy ratings||Purchase strong ratings||Rating score|
Arch Therapeutics currently has a price consensus of $ 3.00, suggesting a potential increase of 669.23%. Mazor Robotics has a consensus price of $ 51.67, suggesting a potential drawback of 11.41%. Considering the stronger rating of the Arch Therapeutics Architectural Board and the growing upward potential, analysts in the field of capital research show that Arch Therapeutics is more favorable than Mazor Robotics.
This table compares the net margins of Arch Therapeutics and Mazor Robotics, return on equity and return on assets.
|Net margins||Return on equity||Return on assets|
|Arch Therapeutics||N / A||-253.72%||-115.60%|
Insider and institutional ownership
0.0% of Arch Therapeutics shares are held by institutional investors. By comparison, 21.7% of Mazor Robotics shares are held by institutional investors. Strong institutional property is an indication that endowments, large money managers and speculative funds believe that a stock is ready for long-term growth.
Arch Therapeutics beat Mazor Robotics on 7 of the 12 factors compared between the two stocks.
About Arch Therapeutics
Arch Therapeutics, Inc., operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leakage as well as provide other benefits during surgery, trauma and interventional care. Its main product candidate is AC5 Devices, a biocompatible synthetic peptide comprising natural amino acids to obtain haemostasis in minimally invasive and open surgical procedures. The company was founded in 2006 and is headquartered in Framingham, Massachusetts.
About Mazor Robotics
Mazor Robotics Ltd., together with its subsidiaries, engages in the development, production and marketing of medical devices to support surgical procedures in the fields of orthopedics and neurosurgery in the United States and internationally. It works in the field of computer-aided surgery, which allows the use of high precision surgical instruments with minimal invasiveness and simplifies complex surgical procedures. Company's robotic surgical guiding systems and complementary products are used to perform the back and brain procedures in a precise and safe manner. It also provides a Mazar X Renaissance system, and its accessories are used in spine surgery including fusion, vertebral correction, biopsy collection, tumor excision, and cement augmentation. The company was known before Mazor Surgical Technologies Ltd. and changed its name to Mazor Robotics Ltd. in 2010. Mazor Robotics Ltd. was founded in 2000 and is headquartered in Caesarea, Israel.
Receive news and ratings for Arch Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest analyst news and assessments for Arch Therapeutics and companies associated with MarketBeat.com's FREE daily newsletter.